AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04021316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandaging therapy
Description: Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
Study NCT03855241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Sheet
Description: The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
Study NCT03594500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No PockeTalker
Description: The control group will not receive PockeTalkers while they receive care in the ED
Study NCT03855241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DisposeRx Drug Disposal kit
Description: DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
Study NCT03024385 — intervention group
Intervention type: BEHAVIORAL
Intervention: Well Child Visits
Description: Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
Study NCT03688945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Attend art viewing sessions
Study NCT03688945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03688945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03688945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04935970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic blood test
Description: vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
Study NCT02771886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surf the Urge
Description: The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors.
Study NCT01656538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT00686855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
Study NCT00686855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
Study NCT04481074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
Study NCT03260010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Infectofos 5 g
Study NCT01656538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01656538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reolysin
Study NCT04967963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAM
Description: Transplantation of HAM
Study NCT01104909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical
Description: Each patient will be submitted a clinical evaluation, considering signals of overload.
Study NCT01104909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical bioimpedance
Description: From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
Study NCT02853370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine and Rituximab
Study NCT04333238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New progress note template
Description: Residents assigned to document with new progress note template
Study NCT04333238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard progress note template
Description: Residents assigned to document with standard progress note template
Study NCT02912585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of own mother's colostrum
Study NCT02912585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oropharyngeal administration of sterile water (placebo)
Study NCT02912585 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal administration of donor human milk
Study NCT03300544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03300544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03300544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT03300544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03300544 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo chemoradiation
Study NCT03300544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given intralesionally
Study NCT03801889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Self-administered by mouth
Study NCT02148289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beverage
Description: Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
Study NCT04935970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological test
Description: neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
Study NCT02148289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate free beverage
Description: Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
Study NCT04244123 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic
Study NCT01049711 — intervention group
Intervention type: DRUG
Intervention: erythropoietin
Study NCT00369655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Study NCT01524679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Description: Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
Study NCT01423656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Study NCT01423656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: LEO 29102 vehicle
Study NCT03074773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action
Study NCT03074773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
Study NCT03074773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
Study NCT03074773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: it is an amino amide local anesthetic drug
Study NCT03074773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
Study NCT02718508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eParenting
Description: The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
Study NCT01874067 — intervention group
Intervention type: DEVICE
Intervention: Arthritis glove
Description: Isotoner three-quarter finger arthritis glove
Study NCT02870179 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: Measurement of physiological parameters
Study NCT02275910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Study NCT01664156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
Study NCT01664156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01641718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tissue glue
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
Study NCT01641718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue glue
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
Study NCT01641718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Staples
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
Study NCT01641718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
Study NCT00090610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin
Study NCT00090610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel
Study NCT02620150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 week trial
Study NCT02620150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 week trial
Study NCT03529461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation through nasal mask
Description: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
Study NCT03688685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-1883
Description: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
Study NCT02783417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion.
Study NCT03529461 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rescue non-invasive positive pressure ventilation through nasal mask
Description: If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
Study NCT03529461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Secondary rescue maneuvers
Description: If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat > 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase > 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
Study NCT03529461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary rescue maneuvers
Description: If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat > 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase > 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
Study NCT03516253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil + EPO
Description: Supplementation with both fish oil and EPO
Study NCT00152178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur) and tamoxifen
Description: UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
Study NCT00152178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
Description: CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
Study NCT03690661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Video Game
Description: The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues.
Study NCT03690661 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Game
Description: The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
Study NCT02188914 — intervention group
Intervention type: RADIATION
Intervention: Positron emission tomography scan
Study NCT02188914 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Study NCT02161250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
Study NCT02161250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
Study NCT00548951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snoezelen Room
Description: Session in a Snoezelen room once per week for 12 weeks
Study NCT00548951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snoezelen Room
Description: Session in a Snoezelen room three times per week for 12 weeks
Study NCT00548951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Receive no sessions in a Snoezelen Room.
Study NCT01752543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan
Description: Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
Study NCT01752543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dextrose)
Description: Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
Study NCT03158974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: East Indian Sandalwood Oil Cream
Description: Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
Study NCT01379001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
Study NCT01379001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM or PO placebo
Study NCT01379001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5mg PO x 1
Study NCT00813566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
Study NCT00813566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
Description: Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
Study NCT00813566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [15O]-H2O
Description: Brain scan with imaging agent to determine tumor blood flow
Study NCT00813566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Acetate
Description: Brain scan with imaging agent to determine growth activity of tumor
Study NCT03938714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Excision of third and fourth degree hemorrhoids
Study NCT03938714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Description: Excision of third and fourth degree hemorrhoids